WW Shares Surge On Heels Of Q4 Report, CEO Says Weight Watchers Is 'Evolving' In GLP-1 Era

WW International, Inc. (NASDAQ:WW) shares soared after it beat fourth-quarter (Q4) fiscal 2025 analyst expectations on revenue and GAAP earnings per share.

The company formerly known as Weight Watchers continues shifting its business toward clinical weight management services. On Monday, it reported:

• A Q4 GAAP loss of 58 cents per share, beating the analyst estimate for a loss of 62 cents per share.
• Revenue totaled $162.8 million, exceeding the $149.1 million consensus estimate.
• Total revenue declined 12% year over year from $184.4 million in the prior-year quarter.
• Subscription revenue reached $161.5 million; clinical subscription revenue increased 32% year over year to $27 million.
• A net loss of $6 million for the quarter, resulting in a net loss margin of 3.6%.
• Adjusted EBITDA was $18 million with an adjusted EBITDA margin of 11.1%.

WW Subscriber Growth, Business Mix

WW ended the quarter with 2.8 million total subscribers. End-of-period clinical subscribers reached 130,000, up 42% year over year.

Clinical subscription revenue represented 17% of total subscription revenue in the quarter, compared with 11% in the fourth quarter of 2024.

For the full year, revenue declined 9.6% to approximately $710.6 million from $785.9 million in the prior year. Behavioral subscription revenue fell 15.2% to $592.6 million, while clinical subscription revenue rose 44.7% to $112.8 million.

Chief Executive Tara Comonte: GLP-1 medications are driving “a profound transformation” in the weight-loss industry, and WW is “evolving” by expanding its clinical capabilities and building digital experiences.

“Our strategy is rooted in combining access to GLP-1 medications with the behavioral support and community that have defined Weight Watchers for decades,” she said.

Financial Position And Outlook

Cash and cash equivalents totaled $160 million at Dec. 31. Total assets stood at $946.8 million, while total liabilities were $628.7 million, including $465.5 million in long-term debt.

For fiscal 2026, WW expects revenue between $620 million and $635 million, compared with the $633.4 million analyst estimate.

The company also forecasts adjusted EBITDA between $105 million and $115 million and projects approximately 2.65 million total subscribers at the end of the first quarter of 2026, including about 200,000 clinical subscribers.

Price Action: WW shares are trading 15.75% higher at $24.40 at the last check on Monday.

Photo Courtesy: Jonathan Weiss On Shutterstock.com